Floatz logo

Toripalimab

Toripalimab

Fudan Universitymonoclonal_antibodyPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Toripalimab cohort.

Asset / SponsorPhaseRating
Sorafenib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3B
Surufatinib
Sun Yat-sen University
Phase 2CCC
Irinotecan
Sun Yat-sen University
Phase 2CCC
ETOPOSIDE
Sun Yat-sen University
Phase 2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Sun Yat-sen University
Phase 2CCC
(+)-VINCRISTINE
Sun Yat-sen University
Phase 2CCC
Carboplatin
Sun Yat-sen University
Phase 2CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Chinese Academy of Medical Sciences
Phase 2CCC

Same molecule, other indications

Toripalimab is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
melanomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →